Physician profile
Umer Hashmi
NPI 1609221639
$1,441.40
in general payments reported to CMS, 2019-2025
18 companies · $557 in 2025
The $557 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $133 · 2023: $213 · 2024: $539 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,308.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $221.62 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $193.77 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $182.20 | 2023-2025 | |
| Abbvie INC. | $142.22 | 2023-2025 | |
| Lilly USA, LLC | $132.02 | 2022-2025 | Zepbound, Mounjaro, Trulicity |
| Gilead Sciences, INC. | $95.57 | 2022-2025 | |
| Amgen INC. | $94.34 | 2024-2025 | Repatha, Otezla, Repatha |
| Viiv Healthcare Company | $54.13 | 2023-2025 | Apretude |
| Glaxosmithkline, LLC. | $47.94 | 2022-2025 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $45.70 | 2024-2025 | Vaqta, Gardasil 9, Capvaxive |
| Abbott Laboratories | $40.12 | 2023-2025 | Freestyle Libre 3 |
| Edwards Lifesciences Corporation | $39.63 | 2024 | Sapien 3 Ultra Resilia |
| Exact Sciences Corporation | $36.18 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $28.86 | 2024-2025 | Veozah |
| Allergan, INC. | $25.03 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $22.74 | 2024 | Spravato |
| Cipher Pharmaceuticals US LLC | $22.60 | 2025 | Spinosad, Natroba |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.73 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umer Hashmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.